Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD0305 |
| Synonyms | |
| Therapy Description |
AZD0305 is an antibody-drug conjugate (ADC) targeting GPRC5D, which potentially induces antibody-dependent cellular cytotoxicity in tumor cells expressing GPRC5D (Blood (2024) 144 (Supplement 1): 2000.2). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD0305 | AZD-0305|AZD 0305 | AZD0305 is an antibody-drug conjugate (ADC) targeting GPRC5D, which potentially induces antibody-dependent cellular cytotoxicity in tumor cells expressing GPRC5D (Blood (2024) 144 (Supplement 1): 2000.2). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06106945 | Phase Ib/II | AZD0305 | A Phase I/II Study of AZD0305 for Relapsed/Refractory Multiple Myeloma | Recruiting | USA | FRA | ESP | DEU | CAN | AUS | 2 |